MD — Pediatrix Medical Group, Inc. stock price, charts and financials
QT82Pediatrix Medical Group, Inc.Pediatrix Medical Group, Inc. (NYSE: MD) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 12.41 | EPS (ttm) | 2.09 | Insider Own | 8.30% | Shs Outstand | 82.12M | Perf Week | -3.14% |
| Market Cap | 2.13B | Forward P/E | 10.63 | EPS next Y | 2.44 | Insider Trans | -0.53% | Shs Float | 80.81M | Perf Month | -1.11% |
| Enterprise Value | 2.33B | PEG | - | EPS next Q | 0.63 | Inst Own | - | Short Float | 5.96% | Perf Quarter | 9.83% |
| Income | 176.00M | P/S | 1.09 | EPS this Y | 12.33% | Inst Trans | - | Short Ratio | 6.07 | Perf Half Y | 30.37% |
| Sales | 1.95B | P/B | 2.42 | EPS next Y | 3.91% | ROA | 8.21% | Short Interest | 4.82M | Perf YTD | 21.22% |
| Book/sh | 10.73 | P/C | 5.27 | EPS next 5Y | -2.59% | ROE | 19.89% | 52W High | 27.94 -7.19% | Perf Year | 60.26% |
| Cash/sh | 4.92 | P/FCF | 9.60 | EPS past 3/5Y | 34.91% - | ROIC | 9.57% | 52W Low | 15.70 65.16% | Perf 3Y | 107.44% |
| Dividend Est. | - | EV/EBITDA | 8.77 | Sales past 3/5Y | -0.99% 1.99% | Gross Margin | 25.95% | Volatility | 3.95% 2.95% | Perf 5Y | -11.86% |
| Dividend TTM | - | EV/Sales | 1.20 | EPS Y/Y TTM | 275.63% | Oper. Margin | 11.60% | ATR (14) | 0.89 | Perf 10Y | -61.47% |
| Dividend Ex-Date | - | Quick Ratio | 1.32 | Sales Y/Y TTM | -3.08% | Profit Margin | 8.96% | RSI (14) | 43.60 | Recom | 2.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.32 | EPS Q/Q | 18.87% | SMA20 | -2.64% | Beta | 0.59 | Target Price | 26.60 |
| Payout | 0.00% | Debt/Eq | 0.76 | Sales Q/Q | 4.05% | SMA50 | -1.58% | Rel Volume | 2.57 | Prev Close | 25.49 |
| Employees | 4,280 | LT Debt/Eq | 0.72 | Earnings | Nov 02 | SMA200 | 12.20% | Avg Volume | 800.45K | Price | 25.93 |
| IPO Date | Sep 20, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.60% 1.94% | Net Debt/EBITDA | 1.24 | Volume | 2,056,957 | Change | 1.73% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-19-26 | Downgrade | Jefferies | Buy → Hold | $27 → $28 |
| Aug-06-26 | Reiterated | UBS | Neutral | $25 → $28 |
| Aug-05-26 | Reiterated | Deutsche Bank | Hold | $19 → $25 |
| Jul-14-26 | Reiterated | Truist Securities | Hold | $21 → $28 |
| May-12-26 | Reiterated | UBS | Neutral | $22 → $25 |
| May-08-26 | Reiterated | Mizuho Securities | Neutral | $21 → $24 |
| Apr-20-26 | Reiterated | Jefferies | Buy | $24 → $27 |
| Feb-24-26 | Reiterated | UBS | Neutral | $23 → $22 |
| Feb-20-26 | Reiterated | Deutsche Bank | Hold | $21 → $19 |
| Nov-10-25 | Reiterated | Truist Securities | Hold | $17 → $24 |
Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,951 | 1,914 | 2,013 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,444 | 1,442 | 1,559 | — | — | — | — | — | — | |
| Gross Profit | 505 | 472 | 454 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 248 | 241 | 238 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 32 | 0 | 285 | — | — | — | — | — | — | |
| Operating Income | 227 | 231 | -69 | — | — | — | — | — | — | |
| Interest Expense | 28 | 36 | 41 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | 21 | 8 | — | — | — | — | — | — | |
| Net Income Before Taxes | 227 | 216 | -101 | — | — | — | — | — | — | |
| Income Taxes | 51 | 51 | -2 | — | — | — | — | — | — | |
| Consolidated Net Income | 176 | 165 | -99 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 176 | 165 | -99 | — | — | — | — | — | — | |
| Net Income | 176 | 165 | -99 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.11 | 1.94 | -1.19 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.11 | 1.94 | -1.19 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.09 | 1.94 | -1.19 | — | — | — | — | — | — | |
| EBITDA | 266 | 274 | -28 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 12.41 | 11.03 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.05 | 0.95 | 0.54 | — | — | — | — | — | — | |
| Gross Margin | 25.88 | 24.66 | 22.55 | — | — | — | — | — | — | |
| Operating Margin | 11.64 | 12.07 | -3.43 | — | — | — | — | — | — | |
| Net Margin | 9.02 | 8.62 | -4.92 | — | — | — | — | — | — | |
| Shares Outstanding | 79 | 85 | 83 | — | — | — | — | — | — | |
| Market Capitalization | 2,048 | 1,818 | 1,089 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Weis Shirley A | Director | May 13 '26 | Sale | 23.75 | 36,028 | 855,665 | 0 | May 14 |
| ORDAN MARK S | Chief Executive Officer | Dec 15 '25 | Sale | 22.41 | 23,000 | 515,430 | 302,805 | Dec 17 |
| Rucker Michael A. | Director | Nov 17 '25 | Sale | 23.00 | 10,478 | 240,994 | 59,101 | Nov 19 |
| Linynsky Laura A | Director | Nov 06 '25 | Sale | 21.65 | 10,000 | 216,500 | 32,232 | Nov 10 |
| ORDAN MARK S | Director | Nov 13 '24 | Sale | 15.35 | 27,600 | 423,660 | 138,683 | Nov 14 |
| Moore Mary Ann E | EVP, GC, Chief Admin Off & Sec | Nov 08 '24 | Sale | 16.00 | 8,108 | 129,728 | 135,810 | Nov 12 |
| Swift James D | Chief Executive Officer | Aug 30 '24 | Sale | 10.79 | 11,100 | 119,769 | 170,001 | Sep 03 |
| Linynsky Laura A | Director | Aug 27 '24 | Sale | 11.16 | 7,000 | 78,120 | 30,805 | Aug 29 |
| Richards C Marc | EVP, Chief Financial Officer | Aug 12 '24 | Sale | 10.08 | 17,438 | 175,775 | 175,347 | Aug 13 |
| Richards C Marc | EVP, Chief Financial Officer | Aug 09 '24 | Sale | 10.08 | 32,562 | 328,225 | 192,785 | Aug 13 |
| Moore Mary Ann E | EVP, General Counsel & Sec | Dec 14 '23 | Sale | 9.62 | 2,120 | 20,394 | 15,730 | Dec 15 |
| Swift James D | Chief Executive Officer | Dec 14 '23 | Sale | 9.58 | 5,764 | 55,219 | 90,874 | Dec 15 |
| Swift James D | Chief Executive Officer | Jun 14 '23 | Sale | 14.14 | 13,193 | 186,549 | 96,638 | Jun 16 |
| ORDAN MARK S | Director | May 25 '23 | Sale | 13.26 | 33,000 | 437,580 | 147,923 | May 26 |
| Weis Shirley A | Director | May 19 '23 | Sale | 13.63 | 1,007 | 13,725 | 17,668 | May 22 |